Centaurus Financial’s Forte Biosciences FBRX Stock Holding History

Centaurus Financial’s Portfolio FBRX Stock Details FBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-3	Closed	-$12K	–	1024
2018 Q2	$12K	Buy	+3	New	+$11K	﹤0.01%	1473

Other funds holding FBRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

Centaurus Financial's FBRX Position: Q3 2018 in Review

Centaurus Financial sold out of Forte Biosciences (FBRX) in Q3 2018, closing a stake of 3 shares — an estimated $12K sold.

Centaurus Financial first reported a position in FBRX in Q2 2018 and held it in 1 quarter. The position peaked at $12K in Q2 2018. 63 funds tracked by Wall St. Rank hold FBRX as of Q3 2018.

Centaurus Financial reported no remaining Forte Biosciences position as of Q3 2018 after selling out during the quarter.
Centaurus Financial sold 3 Forte Biosciences shares in Q3 2018, an estimated $12K.
Centaurus Financial first reported a position in Forte Biosciences in Q2 2018 and held it in 1 quarter.
Centaurus Financial's Forte Biosciences position peaked at $12K in Q2 2018.
63 funds tracked by Wall St. Rank held Forte Biosciences as of Q3 2018.

Based on Centaurus Financial's 13F filing for Q3 2018, filed 5 Nov 2018.